Clinical trial
Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and…
NCT00184002 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00184002 |
|---|---|
| Title | Doxorubicin (Doxil) Combined With Rituxan, Cyclophosphamide, Vincristine and Prednisone in Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas |
| Official title | A Phase II Study Of Pegylated Liposomal Doxorubicin (Doxil) In Combination With Rituxan, Cyclophosphamide, Vincristine and Prednisone (DR-COP) In Newly Diagnosed Aggressive Non-Hodgkin's Lymphomas |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Ortho Biotech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone |
| Enrollment | 68 |
| Start date | Jan 10, 2003 |
| Primary completion | Dec 19, 2012 |
| Completion | May 7, 2013 |
| First posted | Sep 16, 2005 |
| Last update posted | Aug 10, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: